Among patients with HIV-1 suppression while receiving bictegravir–emtricitabine–tenofovir alafenamide (B/F/TAF), switching to weekly islatravir–lenacapavir was noninferior to continuing daily B/F/TAF in maintaining suppression. Full phase 3 ISLEND-1 trial results: https://nej.md/4b4s7sh #AIDS2026
